FDA's National Center for Toxicological Research (NCTR) longer-term studies

• FDA plans to nominate acrylamide to the National Toxicology Program

• FDA will request subchronic toxicity studies, chronic carcinogenicity studies, and mechanistic studies

• NCTR will conduct these studies through interagency agreement with the National Institute for Environmental Health Sciences (NIEHS)

• FDA will participate in all experimental protocol designs to assure regulatory needs are met